Bio-Techne Corp (TECH) has had an assortment of noteworthy developments and news recently. For starters, its current market value sits at US$71.48, with its stock consistently outperforming competitors despite daily losses. Despite some short-term interest in the company dropping by 14.0%, the overall consensus among analysts is a 'Moderate Buy'. Bio-Techne continues to strategize its growth by establishing new distribution partnerships with medtech companies such as Medsantek, Leader Life Sciences, and Thermo Fisher Scientific. These deals aim to broaden its product footprint along with its recent acquisition of Lunaphore aimed at boosting its cancer diagnostic capabilities through spatial biology. Furthermore, collaborations with AlzPath, and Nikon Instruments Inc., aim to advance innovative research and services in their respective fields. The company's financial performance, particularly in its diagnostic growth, has exceeded profit estimates despite some mixed reviews on financials. On the research and development front, it has marked significant milestones, from launching the ESR1 Mutation Monitoring Assay to presenting at several health care conferences, showing an active role in promoting healthcare developments.
Bio-Techne Corp TECH News Analytics from Mon, 03 Aug 2020 07:00:00 GMT to Fri, 03 Jan 2025 12:22:23 GMT -
Rating 7
- Innovation 8
- Information 9
- Rumor -5
